15,682 Shares in Illumina, Inc. $ILMN Acquired by Private Advisory Group LLC

Private Advisory Group LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,682 shares of the life sciences company’s stock, valued at approximately $4,292,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Illumina during the second quarter worth $3,374,423,000. Plato Investment Management Ltd acquired a new stake in Illumina in the second quarter valued at approximately $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Illumina in the 2nd quarter valued at $30,501,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Illumina during the second quarter worth about $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Illumina during the 2nd quarter worth approximately $6,711,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Key Headlines Impacting Illumina

Investors following ILMN have been watching these headlines:

• Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
• Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
• Negative Sentiment: Director Keith Meister sold 280,091 shares over November 9–11 for approximately $61.1 million, reducing his direct holdings to 208,826 shares. The scale of the sales could raise concerns among investors, despite his continuing substantial ownership. SEC filing

Insider Transactions at Illumina

In other news, CAO Scott D. Ericksen sold 267 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total value of $58,141.92. Following the sale, the chief accounting officer directly owned 14,029 shares in the company, valued at $3,054,955.04. This represents a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 98,833 shares of the stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total value of $21,433,912.71. Following the sale, the director owned 208,826 shares in the company, valued at approximately $45,288,094.62. This trade represents a 32.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 1,881,899 shares of company stock worth $415,905,954. 2.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Guggenheim raised their price target on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 target price on shares of Illumina in a report on Friday, July 31st. Evercore reissued an “underperform” rating on shares of Illumina in a research report on Friday, October 30th. Stifel Nicolaus increased their price target on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Stephens downgraded Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price target on the stock. in a research note on Friday, October 23rd. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $244.24.

Illumina Stock Performance

NASDAQ ILMN opened at $209.55 on Friday. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35. The business’s 50-day moving average price is $249.32 and its 200 day moving average price is $179.36. The firm has a market cap of $31.68 billion, a P/E ratio of 36.07, a P/E/G ratio of 2.89 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the previous year, the firm posted $1.34 EPS. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, equities research analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current year.

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.